n.a. (CHTP)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Insider Sells $8.3M Worth of Complete Production Svs

Shareholder L. E. Simmons sells 561,422 shares of CPX.

GenVec, Allied Defense: Early Volume Plays

Several stocks trading near $5 were poised to move on above-average volume during Tuesday's session.

Biotech Stock Mailbag: Poniard Predictions

Readers chime in on Poniard Pharmaceuticals, Chelsea Therapeutics, AMAG, Cel-Sci and Dendreon.

YRC Worldwide: Midday Volume Movers

YRC Worldwide: Midday Volume Movers

Several small-cap stocks were moving on above-average volume during Tuesday's session

Chelsea Just Got Riskier: BioBuzz

Chelsea Just Got Riskier: BioBuzz

Change sought in a phase III trial adds risk and uncertainty.

Biotech Calendar: Key Dates for November

Your quick-and-dirty guide to key dates and events for biotech investors during November.

Biotech Calendar: Key Upcoming Trials

Your quick-and-dirty guide to upcoming phase III clinical trials.

Biotech Stock Mailbag: Oncothyreon

Biotech Stock Mailbag: Oncothyreon

Readers write in about Oncothyreon, Progenics, Chelsea Therapeutics and more.

Cell Therapeutics' Opaxio Data Not Terrible: BioBuzz

Cell Therapeutics' Opaxio Data Not Terrible: BioBuzz

More work needs to be done before penciling in approval.

The Long Trade on Chelsea Therapeutics: BioBuzz

The Long Trade on Chelsea Therapeutics: BioBuzz

Risk-reward for this beaten-down stock improves as pivotal study results loom.

Chelsea Therapeutics: Pump Up the Volume

Chelsea Therapeutics: Pump Up the Volume

Chelsea Therapeutics should trade sharply higher Thursday on heavy volume after the biotech company offered good news on its Droxidopa drug.

Chelsea Trial Flops; Shares Rise After the Fall

Chelsea Trial Flops; Shares Rise After the Fall

Chelsea Therapeutics says its hypotension drug failed, sending shares on a 61% free fall on Thursday.

Biotech Stock Mailbag: Chelsea Therapeutics

Biotech Stock Mailbag: Chelsea Therapeutics

Readers weigh in on Chelsea's rheumatoid arthritis duo, Generex's diabetes spray, AMAG's stock dip, and Anadys' prospects.

Sequenom Fallout Hits Hedge Funds

Investors are selling biotech stocks owned by two hedge funds that took highly concentrated positions in Sequenom on fears that they may be forced to liquidate their other holdings.

Friday's Health Winners & Losers

Friday's Health Winners & Losers

Tercica climbs after swinging to a quarterly profit.

Monday's Health Winners & Losers

Chelsea rises.

Thursday's Health Winners & Losers

Chelsea rises.

Thursday's Small-Cap Winners & Losers

California Water Service falls.

Tuesday's Health Winners & Losers

Tuesday's Health Winners & Losers

Chelsea Therapeutics is stronger.